Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Omipalisib - GlaxoSmithKline

Next Previous
Drug Profile

Omipalisib - GlaxoSmithKline

Alternative Names: 2126458; GSK-212; GSK-2126458; GSK-458

Latest Information Update: 28 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; GSK
  • Class Antineoplastics; Benzene derivatives; Fluorobenzenes; Pyridazines; Pyridines; Quinolines; Small molecules; Sulfonamides
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Acute myeloid leukaemia; Idiopathic pulmonary fibrosis; Lymphoma; Solid tumours

Most Recent Events

  • 28 Jan 2026 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in United Kingdom (PO, Tablet)
  • 09 Jun 2022 Pharmacodynamics data from a cell line study in acute myeloid lukaemia presented at the 27th Congress of the European Haematology Association (EHA-2022)
  • 11 Dec 2021 Preclinical trials in Acute myeloid leukaemia in United Kingdom (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top